Clinical Sofosbuvir-based Therapies Achieved Satisfactory Virological Response In Chinese With Genotypes 3 And 6 Infection: A Real World Experience

Background: As previously shown by others,sofosbuvir-based regimens yield high sustained virological response rates in patients with HCV infection except for genotype 3b complicating with cirrhosis.The real-world study aims to explore efficacy and safety of sofosbuvir-based regimens in genotypes 3 and 6 infected patients,especially the impact of ribavirin co-administration on sustained virological response in cirrhotic patients with genotype 3b infection.Methods: A retrospective cohort study included 101 patients initiated on sofosbuvir-based regimens.Main endpoint of treatment was sustained virological response at post-treatment week 12(SVR12).Result: Overall,SVR12 rate was 95.0%(96/101),similar in 6regimens,100% in sofosbuvir,88.2% in sofosbuvir+ribavirin,100% in sofosbuvir+daclatasvir,100% in sofosbuvir+daclatasvir+ribavirin,95.0%in sofosbuvir/velpatasvir,and 97.1% in sofosbuvir/velpatasvir+ribavirin(p=0.534).SVR12 rates were comparable in patients infected with genotypes 3 and 6(93.2% versus 97.6%,p=0.339).SVR12 rate was 93.9%in cirrhotic patients(31/33),among whom infected with genotype 3,SVR12 rate was achieved in 91.7%(22/24),95.0% with ribavirin coadministration regimens,numerically higher than 75.0% without ribavirin(p=0.312).Totally,five patients failed to achieve SVR12,including 3patients with genotype 3b infection treated with ribavirin co-administration regimens(one of them was cirrhotic),1 cirrhotic patient with genotype 3k infection and 1 non-cirrhotic patient with genotype 6a infection.No sever adverse events occurred.Conclusion: Real-world data show that sofosbuvir-based regimens are highly effective and safe for patients with HCV genotypes 3 and 6 infection.Cirrhotic patients with genotype 3 infection may benefit from ribavirin coadministration.